A Case Report on Prolonged Response with Trastuzumab Emtansine (T-DM1) in Recurrent Advance Breast Cancer Setting

• Praneet Singh Bedi

  Department of Medical Oncology, Max Super Speciality Hospital, Delhi 110092, India

  https://orcid.org/0009-0001-9641-0578

• Meenu Walia

  Department of Medical Oncology, Max Super Speciality Hospital, Delhi 110092, India

  https://orcid.org/0009-0004-3530-3578

• Vipulkumar Thummar

  Medical Affairs, Zydus Lifesciences Ltd., Ahmedabad 382481, India

  https://orcid.org/0000-0002-2781-9898

• Priya Mehta

  Medical Affairs, Zydus Lifesciences Ltd., Ahmedabad 382481, India

  https://orcid.org/0000-0002-0886-9670

Breast cancer holds the dubious distinction of being the most prevalent malignant tumor among women worldwide the 5 year survival rate for patients with advanced or metastatic forms of the disease is estimated at a mere 23%, with approximately 20% of cases exhibiting an amplification of the human epidermal growth factor receptor 2 (HER2). HER2 overexpression was linked to a dismal prognosis prior to the advent of targeted HER2 therapies. The introduction of ado-trastuzumab emtansine (T-DM1) has emerged as one of the standard treatment options for HER2-positive breast cancer patients who experience a recurrence or progression of the disease. This case concerns a patient with recurrent metastatic breast cancer who achieved an unusually extended period of time without the disease progressing while on T-DM1 treatment. After experiencing disease progression on multiple treatment lines involving trastuzumab, the patient achieved a nearly complete clinical remission (cCR) with T-DM1 therapy. The availability of cost-effective biosimilars has expanded access to advanced biologic therapies, which were previously limited to a small segment of the population due to the cost barrier.

Manthri S, Singal S, Youssef B, Chakraborty K. Long-time response with ado-trastuzumab emtansine in a recurrent metastatic breast cancer. Cureus 2019; 11(10): e6036. https://doi.org/10.7759/cureus.6036

Sun L, Gan L, Wang T. T-DM1 for advanced breast cancer after multi-anti-HER2-target therapy: a case report. Transl Breast Cancer Res 2021; 2: 15. https://doi.org/10.21037/tbcr-21-70

Cantini L, Pistelli M, Savini A, Bastianelli L, Della Mora A, Merloni F, et al. Long-responders to anti-HER2 therapies: A case report and review of the literature. Mol Clin Oncol 2018; 8(1): 147-52. https://doi.org/10.3892/mco.2017.1495

Zimmer AS, Van Swearingen AED, Anders CK. HER2-positive breast cancer brain metastasis: A new and exciting landscape. Cancer Rep (Hoboken) 2022; 5(4): e1274. https://doi.org/10.1002/cnr2.1274

Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-91. Correction in: N Engl J Med 2013; 368: 2442. https://doi.org/10.1056/NEJMoa1209124

Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 2017; 18: 732-42. Erratum in: Lancet Oncol Erratum in 2018; 19: e667. 2017; 18: e433. https://doi.org/10.1016/S1470-2045(17)30312-1

Krop IE, Kim SB, González-Martín A, LoRusso PM, Ferrero JM, Smitt M, et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15(7): 689-99. https://doi.org/10.1016/S1470-2045(14)70178-0

Krop IE, Kim SB, Martin AG, LoRusso PM, Ferrero JM, Badovinac-Crnjevic T, et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol 2017; 18(6): 743-54. https://doi.org/10.1016/S1470-2045(17)30313-3

Ricciardi GRR, Russo A, Franchina T, Schifano S, Mastroeni G, Santacaterina A, et al. Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review. BMC Cancer 2018; 18(1): 97. https://doi.org/10.1186/s12885-018-3994-5

Montemurro F, Delaloge S, Barrios CH, Wuerstlein R, Anton A, Brain E, et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆. Ann Oncol 2020; 31(10): 1350-8. https://doi.org/10.1016/j.annonc.2020.06.020

Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol 2015; 26(1): 113-9. https://doi.org/10.1093/annonc/mdu486

• PDF

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.